Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands |
12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2016 |
Jun. 21, 2017 |
Mar. 31, 2017 |
|
Business combination, contingent consideration liabilities | $ 232 | $ 260 | ||
Reduction in the fair value of the contingent consideration | (5,795) | (11,860) | ||
Pre-Funded Warrants [Member] | ||||
Warrant to purchase shares of common stock | 2,600,000 | |||
Underwriter Warrants[Member] | ||||
Warrant to purchase shares of common stock | 575,000 | |||
Asuragen and Redpath [Member] | ||||
Reduction in the fair value of the contingent consideration | $ 11,900 | |||
RedPath Integrated Pathology, Inc [Member] | Termination Agreement [Member] | ||||
Business combination, contingent consideration liabilities | $ 6,000 | |||
Business combination, operating expenses | $ 5,800 |
X | ||||||||||
- Definition Business combination, operating expenses. No definition available.
|
X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|